Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis after Laparoscopic Surgery for Colorectal Cancer Rivaroxaban or Placebo for Extended Antithrombotic Prophylaxis after Laparoscopic Surgery for Colorectal Cancer Haemin Go / Tuesday, July 12, 2022 0 824 Article rating: No rating Tuesday, July 12, 2022 July 12, 2022 | Cecilia Becattini, M.D., University of Perugia, Perugia, Italy Read more
FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy FRONTIER1: A Phase 1/2 Dose Escalation Study of a Novel Factor VIIIa Mimetic Bispecific Antibody, Mim8, for Evaluation of Safety, Pharmacokinetics and Efficacy Haemin Go / Monday, July 11, 2022 0 967 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Pratima Chowdary, M.D., F.R.C.Path., Royal Free Hospital, London, United Kingdom Read more
Von Willebrand Factor–Targeting Thrombolysis to Overcome Tissue Plasminogen Activator Resistance In Vivo Von Willebrand Factor–Targeting Thrombolysis to Overcome Tissue Plasminogen Activator Resistance In Vivo Haemin Go / Monday, July 11, 2022 0 794 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Coen Maas, Ph.D., University Medical Center Utrecht, Utrecht University, Utrecht, the Netherlands Read more
Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome Activation of the Plasma Contact System Triggers the Fat Embolism Syndrome Haemin Go / Monday, July 11, 2022 0 603 Article rating: No rating Monday, July 11, 2022 July 11, 2022 | Sandra Konrath, M.Sc., University Medical Center Hamburg-Eppendorf (UKE), Hamburg, Germany Read more
Early Career Researchers Receive Editors' Awards Early Career Researchers Receive Editors' Awards Haemin Go / Monday, July 11, 2022 0 2052 Article rating: No rating Monday, July 11, 2022 Read more